Enhanced dissolution rate of simvastatin using spherical crystallization technique

Pharmaceutical Development and Technology

Volumn 16, Issue 5, 2011, Pages 529-535

  Varshosaz, Jaleh ^a   Tavakoli, Naser ^a   Salamat, Fatemeh Akhavan ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

DSC; Enhanced solubility; FTIR; Simvastatin; Spherical crystallization; XRPD

Indexed keywords

DICHLOROMETHANE; DODECYL SULFATE SODIUM; ISOPROPYL ACETATE; PHOSPHATE BUFFERED SALINE; SIMVASTATIN; SOLVENT; UNCLASSIFIED DRUG; WATER;

ARTICLE; CRYSTAL; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; HUMIDITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; PARTICLE SIZE; PHARMACOLOGICAL PROCEDURES; POWDER; PRIORITY JOURNAL; SEDIMENTATION; SPHERICAL CRYSTALLIZATION TECHNIQUE; X RAY POWDER DIFFRACTION;

ANTICHOLESTEREMIC AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CRYSTALLIZATION; DIFFUSION; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDERS; SIMVASTATIN; SOLUBILITY; SOLVENTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TEMPERATURE; X-RAY DIFFRACTION;

EID: 80052906174     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2010.502175     Document Type: Article

References (32)

1. Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G, Lee HB, Cho SH. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 2004;274(1-2):65-73. (Pubitemid 38457007)
2. g drug: In vitro and in vivo evaluations. Pharm Res 2005;22:990-998. (Pubitemid 40898109)
3. Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G, Lee HB, Cho SH. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 2004;274:65-73. (Pubitemid 38457007)
4. Jun SW, Kim MS, Kim JS, Park HJ, Lee S, Woo JS, Hwang SJ. Preparation and characterization of simvastatin/hydroxypropyl-β-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 2007;6(3):413-421. (Pubitemid 46756217)
5. Burcham DL, Maurin MB, Hausner EA, Huang SM. Improved oral bioavailability of the hypocholesterolemic DMP 565 in dogs following oral dosing in oil and glycol solutions. Biopharm Drug Dispos 1997;8:373-742.
6. Serajuddin ATM, Sheen PC, Mufson D, Bernstein DF, Augustine MA. Efect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersion. J Pharm Sci 1988;7:414-417. (Pubitemid 19080862)
7. Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. Self-emulsifying drug delivery systems (SEDDS) with polyglycolysed glycerides or improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 1994;6:15-23. (Pubitemid 24110060)
8. Kararli TT, Needham TE, Grifæn M, Schoenhard G, Ferro LJ, Alcorn L. Oral delivery of a renin inhibitor compound using emulsion formulations. Pharm Res 1992;9:888-893.
9. Schwendener RA, Schott H. Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. J Cancer Res Clin Oncol 1996;122:723-726. (Pubitemid 26393240)
10. Varshosaz J, Talari R, Mostafavi SA, Nokhodchi A. Dissolution enhancement of gliclazide using in situ micronization by solvent change method. Powder Technol 2008;187(3):222-230.
11. Talari R, Varshosaz J, Nokhodchi A. Dissolution enhancement of gliclazide using pH change approach. J Pharm Pharmaceut Sci 2009;12 (3):250-265.
12. Patel R, Buckton G, Gaisford S. Te use of isothermal titration calorimetry to assess the solubility enhancement of simvastatin by a range of surfactants. Termochimica Acta 2007;456(2):106-113. (Pubitemid 46541648)
13. Fages J, Lochard H, Letourneau JJ, Sauceau M, Rodier E. Particle generation for pharmaceutical applications using supercritical fuid technology. Powder Technol 2004;141:219-226. (Pubitemid 38726140)
14. Jun SW. Inclusion complex of simvastatin with hydroxypropyl-beta- cyclodextrin using supercritical antisolvent (SAS) process. MS Tesis, Chungnam National University, Daejeon, Korea; 2006.
15. Wen X, Liu Z, Zhu T. Mass spectrometry and molecular modeling studies on the inclusion complexes between α,β-cyclodextrins and simvastatin. Chem Phys Lett 2005;405:114-117. (Pubitemid 40454078)
16. Ribardière A, Tchorelof P, Couarraze G, Puisieux F. Modifcation of ketoprofen bead structure produced by the spherical crystallization technique with a two-solvent system. Int J Pharm 1996;144: 195-207. (Pubitemid 27043037)
17. Kawashima Y, Cui F, Takeuchi H, Niwa T, Hino T, Kiuchi K. Improvements in fowability and compressibility of pharmaceutical crystals for direct tabletting by spherical crystallization with a two-solvent system. Powder Technol 1994;78:151-157.
18. Nokhodchi A, Maghsoodi M, Hassanzadeh D. An improvement of physicomechanical properties of carbamazepine crystals. Iranian J Pharm Res 2007;6(2):83-93. (Pubitemid 350142085)
19. Martino PD, Cristofaro RD, Barthélémy C, Joiris E, Filippo GP, Sante M. Improved compression properties of propyphenazone spherical crystals. Int J Pharm 2000;197(1-2):95-106. (Pubitemid 30125781)
20. Katta J, Rasmuson AC. Spherical crystallization of benzoic acid. Int J Pharm 2008;348(1-2):61-69. (Pubitemid 350266240)
21. González DA, Biscans B. Spherical agglomeration during crystallization of an active pharmaceutical ingredient. Powder Tech 2002;128(2-3):188-194. (Pubitemid 35370038)
22. Cui F, Yang M, Jiang Y, Cun D, Lin W, Fan Y, Kawashima Y. Design of sustained-release nitrendipine microspheres having solid dispersion structure by quasi-emulsion solvent difusion method. J Control Rel 2003;91(3,4):375-384. (Pubitemid 36976768)
23. Szabó-Révész P, Farkas B, Gregor T, Nagy K, Pallagi E. Development of spherical iron (II) sulfate heptahydrate-containing solid particles with sustained drug release. Eur J Pharm Biopharm 2007;66(2):193-199. (Pubitemid 46654768)
24. Kawashima Y, Okumura M, Takenaka H, Kojima A. Direct preparation of spherically agglomerated salicylic acid crystals during crystallization. J Pharm Sci 1984;73(11):1535-1538. (Pubitemid 15205523)
25. Di Martino P, Barthélémy C, Piva F, Joiris E, Palmieri GF, Martelli S. Improved dissolution behavior of fenbufen by spherical crystallization. Drug Dev Ind Pharm 1999;25(10):1073-1081. (Pubitemid 29477864)
26. Pawar PH, Pawar AP, Mahadik KR, Paradkar AR. Evalution of tableting properties of agglomerates odtained by spherical crystallisation of trimethoprim. Indian J Pharm Sci 1998;60(1): 24-28. (Pubitemid 28346192)
27. Sano A, Kuriki T, Kawashima Y, Takeuchi H, Hino T, Niwa T. Particle design of tolbutamide by the spherical crystallization technique. III. Micromeritic properties and dissolution rate of tolbutamide spherical agglomerates prepared by the quasi-emulsion solvent difusion method and the solvent change method. Chem Pharm Bull 1990;38(3):733-739. (Pubitemid 20316807)
28. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y, Furuyama S. Characterization of polymorphs of tranilast anhydrate and tranilast monohydrate when crystallized by two solvent change spherical crystallization techniques. J Pharm Sci 1991;80(5): 472-478.
29. Kawashima Y, Takenaka H. Development of agglomeration process by using a focculation phenomenon of particle in liquid and the applications to pharmaceutical system. Hyomen 1984;22: 719-728.
30. Kawashima Y, Imai M, Takeuchi H, Yamamoto H, Kamiya K, Hino T. Improved fowability and compactibility of spherically agglomerated crystals of ascorbic acid for direct tabletting designed by spherical crystallization process. Powder Technol 2003;130(1-3): 283-289. (Pubitemid 36293204)
31. Puechagut HG, Bianchotti J, Chiale CA. Preparation of norfoxacin spherical agglomerates using the ammonia difusion system. J Pharm Sci 1998;87:519-523. (Pubitemid 28175816)
32. Bates S, Ivanisevic I. Percent crystallinity determination from XRPD data using standardless methods. Te AAPS J 2005;7(S2):(Annual Meeting).